- Meeting abstract
- Open Access
PW03-006 - IL-1-B inhibition in Schnitzler’s syndrome
Pediatric Rheumatology volume 11, Article number: A232 (2013)
Schnitzler’s syndrome is a chronic disabling autoinflammatory disorder, characterised by chronic urticaria, paraproteinemia and systemic inflammation. The interleukin (IL) 1 receptor antagonist anakinra is a very effective treatment, but requires daily injection and blocks both IL-1α and IL-1β. Canakinumab is a selective human monoclonal anti-IL-1β antibody with a long half-life.
We investigated the long-term efficacy and safety of canakinumab in Schnitzler’s syndrome.
In an open-label, single-treatment arm trial, eight patients with Schnitzler’s syndrome received monthly injections with 150 mg canakinumab subcutaneously for 6 months, followed by a 3-month observation period. Primary outcome was complete or clinical remission at day 14. Secondary outcome measures included inflammatory markers, quality of life, time to relapse, safety and tolerability.
After stopping anakinra, patients developed moderate to severe clinical symptoms. Canakinumab induced complete or clinical remission at day 14 in all eight patients. Median C-reactive protein concentrations decreased from 169 mg/l at baseline to less than 10 mg/l on day 14 and remained low or undetectable. One patient discontinued participation on day 39 because of return of symptoms while all others remained in complete or clinical remission during the 6-month treatment period. Relapse after last canakinumab dose occurred within 3 months in four patients. For two patients, remission continued several months post-study. Five patients reported at least one adverse event, predominantly mild upper respiratory tract infections. One patient died in a traffic accident.
In this 9-month study, monthly 150 mg canakinumab injection was an effective and well-tolerated treatment for Schnitzler’s syndrome. Our data demonstrate that IL-1β plays a pivotal role in this disease.
Disclosure of interest
About this article
Cite this article
De Koning, H., Schalkwijk, J., Jongekrijg, J. et al. PW03-006 - IL-1-B inhibition in Schnitzler’s syndrome. Pediatr Rheumatol 11, A232 (2013) doi:10.1186/1546-0096-11-S1-A232
- Clinical Remission
- Secondary Outcome Measure
- Chronic Urticaria